RU2018128793A - Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний - Google Patents
Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний Download PDFInfo
- Publication number
- RU2018128793A RU2018128793A RU2018128793A RU2018128793A RU2018128793A RU 2018128793 A RU2018128793 A RU 2018128793A RU 2018128793 A RU2018128793 A RU 2018128793A RU 2018128793 A RU2018128793 A RU 2018128793A RU 2018128793 A RU2018128793 A RU 2018128793A
- Authority
- RU
- Russia
- Prior art keywords
- active agent
- manganese
- individual
- acceptable salt
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 34
- 238000000034 method Methods 0.000 title claims 22
- 230000001154 acute effect Effects 0.000 title claims 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 title 1
- 206010019663 Hepatic failure Diseases 0.000 title 1
- 231100000334 hepatotoxic Toxicity 0.000 title 1
- 230000003082 hepatotoxic effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 26
- 229910052748 manganese Inorganic materials 0.000 claims 23
- 239000011572 manganese Substances 0.000 claims 23
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 22
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 claims 14
- -1 DPDP compound Chemical class 0.000 claims 12
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 12
- 229960004308 acetylcysteine Drugs 0.000 claims 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 8
- 229910052791 calcium Inorganic materials 0.000 claims 8
- 239000011575 calcium Substances 0.000 claims 8
- UMRUNOIJZLCTGG-UHFFFAOYSA-N calcium;manganese Chemical compound [Ca+2].[Mn].[Mn].[Mn].[Mn] UMRUNOIJZLCTGG-UHFFFAOYSA-N 0.000 claims 7
- 150000004696 coordination complex Chemical class 0.000 claims 7
- 108010024636 Glutathione Proteins 0.000 claims 6
- 229960003180 glutathione Drugs 0.000 claims 6
- 208000007788 Acute Liver Failure Diseases 0.000 claims 5
- 206010000804 Acute hepatic failure Diseases 0.000 claims 5
- 231100000836 acute liver failure Toxicity 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 5
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 5
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 5
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 5
- JFVHALAXWREODT-UHFFFAOYSA-N C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] Chemical compound C(C=1C(CO)=CN=C(C)C1O)NCCN.[Mn] JFVHALAXWREODT-UHFFFAOYSA-N 0.000 claims 4
- 229960005489 paracetamol Drugs 0.000 claims 4
- 206010019851 Hepatotoxicity Diseases 0.000 claims 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims 2
- 230000007686 hepatotoxicity Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018128793A true RU2018128793A (ru) | 2020-02-13 |
| RU2018128793A3 RU2018128793A3 (https=) | 2020-05-25 |
Family
ID=57909814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018128793A RU2018128793A (ru) | 2016-01-11 | 2017-01-10 | Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (https=) |
| EP (2) | EP3842040B1 (https=) |
| JP (2) | JP7311267B2 (https=) |
| CN (1) | CN108601757A (https=) |
| AU (1) | AU2017208123B2 (https=) |
| CA (1) | CA3010915C (https=) |
| RU (1) | RU2018128793A (https=) |
| WO (1) | WO2017122120A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| CA3140096A1 (en) * | 2019-05-21 | 2020-11-26 | Pendulum Therapeutics, Inc. | Methods and compositions for treating liver disorders |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| WO2005017094A2 (en) * | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP2010507572A (ja) * | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| CN105688215A (zh) * | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CN107353313B (zh) * | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| EP3842040B1 (en) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en not_active Not-in-force
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12303516B2 (en) | 2025-05-20 |
| US20190015424A1 (en) | 2019-01-17 |
| JP2019501226A (ja) | 2019-01-17 |
| US11260060B2 (en) | 2022-03-01 |
| RU2018128793A3 (https=) | 2020-05-25 |
| EP3402475A1 (en) | 2018-11-21 |
| CN108601757A (zh) | 2018-09-28 |
| AU2017208123A1 (en) | 2018-07-19 |
| AU2017208123B2 (en) | 2022-04-21 |
| JP7374163B2 (ja) | 2023-11-06 |
| EP3842040A1 (en) | 2021-06-30 |
| EP3402475B1 (en) | 2021-10-20 |
| EP3842040B1 (en) | 2022-03-09 |
| CA3010915A1 (en) | 2017-07-20 |
| JP7311267B2 (ja) | 2023-07-19 |
| WO2017122120A1 (en) | 2017-07-20 |
| JP2022019973A (ja) | 2022-01-27 |
| US20220133739A1 (en) | 2022-05-05 |
| CA3010915C (en) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018128793A (ru) | Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CA1161362A (en) | Pharmaceutical compositions containing a corticosteroid substance | |
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
| JP2019501226A5 (https=) | ||
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| WO2007056232A3 (en) | Methods of using saha and bortezomib for treating cancer | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| JP2016518359A5 (https=) | ||
| RU2014152208A (ru) | Композиции, содержащие апоморфин и органические кислоты, и их применение | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| NZ585219A (en) | Fast release solid formulation, preparation and use thereof | |
| JP2015506989A5 (https=) | ||
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| MX2020008173A (es) | Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. | |
| WO2008057456A3 (en) | Methods of using saha and bortezomib for treating multiple myeloma | |
| JP2022019973A5 (https=) | ||
| JP2016503058A5 (https=) | ||
| RU2016127558A (ru) | Стероидное соединение для применения в лечении печеночной энцефалопатии | |
| RU2019119405A (ru) | Лиофилизированные фармацевтические композиции далбаванцина | |
| MX2024003650A (es) | Metodos de dosificacion de inhibidores de transportador apical de acidos biliares dependiente de sodio (asbtis). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |